CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Acorda Therapeutics, Inc. - ACOR CFD

12.4597
4.18%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.7906
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Acorda Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 11.9597
Open* 11.5997
1-Year Change* 2065.74%
Day's Range* 11.5997 - 12.9597
52 wk Range 8.98-24.20
Average Volume (10 days) 4,120.00
Average Volume (3 months) 85.39K
Market Cap 21.74M
P/E Ratio -100.00K
Shares Outstanding 1.24M
Revenue 111.12M
EPS -12.83
Dividend (Yield %) N/A
Beta 1.43
Next Earnings Date Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 12.4597 0.7200 6.13% 11.7397 12.9597 11.5997
Mar 27, 2024 11.9597 -0.1100 -0.91% 12.0697 12.0697 11.7597
Mar 26, 2024 11.9597 -0.1000 -0.83% 12.0597 12.0797 11.7597
Mar 25, 2024 12.0597 0.0000 0.00% 12.0597 12.2697 12.0597
Mar 22, 2024 12.0597 0.1000 0.84% 11.9597 12.1097 11.9597
Mar 21, 2024 12.0797 -0.3900 -3.13% 12.4697 12.5697 11.9597
Mar 20, 2024 12.4597 -0.5500 -4.23% 13.0097 13.0097 12.3597
Mar 19, 2024 13.2097 -0.2700 -2.00% 13.4797 13.4797 13.2097
Mar 18, 2024 13.4597 1.1000 8.90% 12.3597 13.4597 12.3597
Mar 15, 2024 12.4597 -0.2200 -1.74% 12.6797 12.6797 12.3597
Mar 14, 2024 12.3597 0.0000 0.00% 12.3597 12.5097 12.3597
Mar 13, 2024 12.3597 0.5500 4.66% 11.8097 12.3597 11.7697
Mar 12, 2024 11.9597 0.0000 0.00% 11.9597 12.6197 11.9597
Mar 11, 2024 12.0197 -0.1900 -1.56% 12.2097 12.6597 11.7097
Mar 8, 2024 12.2097 -1.0500 -7.92% 13.2597 13.2597 12.2097
Mar 7, 2024 13.3597 -0.6000 -4.30% 13.9597 13.9697 13.2597
Mar 6, 2024 13.2097 0.0000 0.00% 13.2097 13.4397 12.6797
Mar 5, 2024 12.3597 -0.6000 -4.63% 12.9597 13.3997 11.9597
Mar 4, 2024 13.0997 -0.4600 -3.39% 13.5597 13.7597 12.8597
Mar 1, 2024 13.5597 0.4200 3.20% 13.1397 13.9597 13.1397

Acorda Therapeutics, Inc. Events

Time (UTC) Country Event
Monday, April 1, 2024

Time (UTC)

20:00

Country

US

Event

Q4 2023 Acorda Therapeutics Inc Earnings Release
Q4 2023 Acorda Therapeutics Inc Earnings Release

Forecast

-

Previous

-

Time (UTC)

20:30

Country

US

Event

Q4 2023 Acorda Therapeutics Inc Earnings Call
Q4 2023 Acorda Therapeutics Inc Earnings Call

Forecast

-

Previous

-
Thursday, May 2, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Acorda Therapeutics Inc Earnings Release
Q1 2024 Acorda Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 118.566 129.071 152.967 192.408 471.433
Revenue 118.566 129.071 152.967 192.408 471.433
Cost of Revenue, Total 30.332 40.787 33.513 34.849 99.31
Gross Profit 88.234 88.284 119.454 157.559 372.123
Total Operating Expense 126.764 208.109 231.043 448.967 432.947
Selling/General/Admin. Expenses, Total 105.956 118.999 152.576 192.846 172.254
Research & Development 0.075 0.694 1.745 2.812 5.56
Other Operating Expenses, Total -13.521 10.865 -49.581 -29.664 155.823
Operating Income -8.198 -79.038 -78.076 -256.559 38.486
Interest Income (Expense), Net Non-Operating -28.299 -30.03 -29.758 -17.702 -18.079
Other, Net 1.25 -0.006 0.167 0.013 0.016
Net Income Before Taxes -35.247 -109.074 -107.667 -274.248 20.423
Net Income After Taxes -65.916 -103.954 -99.594 -272.966 18.882
Minority Interest 0
Net Income Before Extra. Items -65.916 -103.954 -99.594 -272.966 18.882
Net Income -65.916 -103.954 -99.594 -272.966 33.682
Income Available to Common Excl. Extra. Items -65.916 -103.954 -99.594 -272.966 18.882
Income Available to Common Incl. Extra. Items -65.916 -103.954 -99.594 -272.966 33.682
Diluted Net Income -65.916 -103.954 -99.594 -272.966 33.682
Diluted Weighted Average Shares 0.98535 0.53105 0.4042 0.39593 0.39451
Diluted EPS Excluding Extraordinary Items -66.896 -195.752 -246.398 -689.424 47.8621
Diluted Normalized EPS -84.6027 -188.408 -146.651 -324.168 47.8621
Unusual Expense (Income) -26.842 6 62.027 222.488 0
Total Extraordinary Items 14.8
Depreciation / Amortization 30.764 30.764 30.763 25.636
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 29.675 22.258 31.47 33.511 31.051
Revenue 29.675 22.258 31.47 33.511 31.051
Cost of Revenue, Total 3.065 3.234 4.56 11.005 8.8
Gross Profit 26.61 19.024 26.91 22.506 22.251
Total Operating Expense 33.307 33.734 4.061 38.5 44.966
Selling/General/Admin. Expenses, Total 21.825 22.514 26.254 22.997 29.967
Research & Development 0.004 0.001 0.009 0.014 0.025
Depreciation / Amortization 7.691 7.691 7.691 7.691 7.691
Unusual Expense (Income) -27.142 0 0.1
Other Operating Expenses, Total 0.722 0.294 -7.311 -3.207 -1.617
Operating Income -3.632 -11.476 27.409 -4.989 -13.915
Interest Income (Expense), Net Non-Operating -7.715 -7.478 -5.835 -7.449 -7.454
Other, Net 0.001 0.092 0 0 1.25
Net Income Before Taxes -11.346 -18.862 21.574 -12.438 -20.119
Net Income After Taxes -9.381 -16.824 19.142 -13.854 -46.682
Net Income Before Extra. Items -9.381 -16.824 19.142 -13.854 -46.682
Net Income -9.381 -16.824 19.142 -13.854 -46.682
Income Available to Common Excl. Extra. Items -9.381 -16.824 19.142 -13.854 -46.682
Income Available to Common Incl. Extra. Items -9.381 -16.824 19.142 -13.854 -46.682
Diluted Net Income -9.381 -16.824 19.142 -13.854 -46.682
Diluted Weighted Average Shares 1.242 1.2169 1.2192 1.2145 0.83915
Diluted EPS Excluding Extraordinary Items -7.55314 -13.8253 15.7005 -11.4072 -55.6301
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -7.55314 -13.8253 1.23007 -11.4072 -55.5526
Gain (Loss) on Sale of Assets
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 82.115 102.157 221.335 201.113 528.107
Cash and Short Term Investments 37.536 45.634 71.369 125.839 445.553
Cash & Equivalents 37.536 45.634 71.369 62.085 293.564
Short Term Investments 0 63.754 151.989
Total Receivables, Net 13.866 17.002 20.193 22.083 23.43
Accounts Receivable - Trade, Net 13.866 17.002 20.193 22.083 23.43
Total Inventory 12.752 18.548 28.677 25.221 29.014
Prepaid Expenses 4.312 6.574 14.807 11.574 19.384
Other Current Assets, Total 13.649 14.399 86.289 16.396 10.726
Total Assets 395.595 455.47 632.68 799.718 1299.67
Property/Plant/Equipment, Total - Net 7.89 11.133 25.744 165.977 60.519
Property/Plant/Equipment, Total - Gross 14.645 46.13 61.768 230.453 117.426
Accumulated Depreciation, Total -6.755 -34.997 -36.024 -64.476 -56.907
Goodwill, Net 0 282.059
Intangibles, Net 305.087 335.98 366.981 402.329 428.57
Other Long Term Assets, Total 0.503 6.2 18.62 30.299 0.411
Total Current Liabilities 37.95 54.025 137.252 86.385 140.256
Accounts Payable 9.809 10.845 12.155 26.257 48.859
Accrued Expenses 24.192 35.043 43.247 43.538 70.269
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 68.631 0.603 0.616
Other Current Liabilities, Total 3.949 8.137 13.219 15.987 20.512
Total Liabilities 301.973 304.333 394.725 488.898 687.683
Total Long Term Debt 167.031 178.67 166.174 218.269 343.14
Long Term Debt 167.031 178.67 166.174 218.269 343.14
Deferred Income Tax 44.202 13.93 19.116 9.581 7.483
Other Liabilities, Total 52.79 57.708 72.183 174.663 196.804
Total Equity 93.622 151.137 237.955 310.82 611.983
Common Stock 0.024 0.013 0.009 0.048 0.048
Additional Paid-In Capital 1029.88 1023.14 1007.79 979.388 1005.1
Retained Earnings (Accumulated Deficit) -936.273 -870.357 -766.403 -666.809 -393.843
Treasury Stock - Common -0.638 -0.638 -0.638 -0.638 -2.133
Other Equity, Total 0.628 -1.017 -2.803 -1.169 2.806
Total Liabilities & Shareholders’ Equity 395.595 455.47 632.68 799.718 1299.67
Total Common Shares Outstanding 1.21688 0.66221 0.4735 0.39752 0.39518
Redeemable Preferred Stock 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 73.728 64.914 68.094 82.115 71.692
Cash and Short Term Investments 32.468 25.27 30.255 37.536 20.696
Cash & Equivalents 32.468 25.27 30.255 37.536 20.696
Total Receivables, Net 11.977 13.39 9.19 13.866 14.69
Accounts Receivable - Trade, Net 11.977 13.39 9.19 13.866 14.69
Total Inventory 17.942 14.797 13.465 12.752 15.252
Prepaid Expenses 5.042 5.48 4.125 4.312 5.111
Other Current Assets, Total 6.299 5.977 11.059 13.649 15.943
Total Assets 366.344 364.696 374.906 395.595 393.339
Property/Plant/Equipment, Total - Net 6.706 6.928 7.412 7.89 8.366
Intangibles, Net 282.006 289.7 297.393 305.087 312.779
Other Long Term Assets, Total 3.904 3.154 2.007 0.503 0.502
Total Current Liabilities 46.294 30.386 34.739 37.95 42.023
Accounts Payable 12.33 3.175 2.854 9.809 11.505
Accrued Expenses 30.922 23.389 28.573 25.225 28.159
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total 3.042 3.822 3.312 2.916 2.359
Total Liabilities 307.387 296.828 297.946 301.973 317.573
Total Long Term Debt 181.043 176.164 171.496 167.031 187.689
Long Term Debt 181.043 176.164 171.496 167.031 187.689
Deferred Income Tax 38.544 39.556 41.805 44.202 42.228
Other Liabilities, Total 41.506 50.722 49.906 52.79 45.633
Total Equity 58.957 67.868 76.96 93.622 75.766
Common Stock 0.001 0.001 0.024 0.024 0.024
Additional Paid-In Capital 1030.24 1030.1 1029.95 1029.88 1029.7
Retained Earnings (Accumulated Deficit) -971.366 -962.478 -953.097 -936.273 -955.415
Treasury Stock - Common -0.638 -0.638 -0.638 -0.638 -0.638
Other Equity, Total 0.717 0.88 0.719 0.628 2.09
Total Liabilities & Shareholders’ Equity 366.344 364.696 374.906 395.595 393.339
Total Common Shares Outstanding 1.2421 1.2421 1.21688 1.21688 1.21663
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -65.916 -103.954 -99.594 -272.966 33.682
Cash From Operating Activities -20.924 -41.348 -61.006 -128.167 150.793
Cash From Operating Activities 32.809 33.953 41.298 34.573 11.479
Non-Cash Items 10.485 3.718 9.244 151.631 58.024
Cash Taxes Paid 0.199 0.05 0.251 2.791 20.709
Cash Interest Paid 7.157 0.006 6.67 6.056 6.064
Changes in Working Capital 1.698 24.935 -11.954 -41.405 47.608
Cash From Investing Activities -0.136 73.778 59.36 -0.505 -176.865
Capital Expenditures -0.136 -0.191 -4.39 -90.426 -33.915
Other Investing Cash Flow Items, Total 0 73.969 63.75 89.921 -142.95
Cash From Financing Activities 0 -69.655 -1.668 -60.55 12.797
Financing Cash Flow Items 0 -1.071 -4.67
Issuance (Retirement) of Stock, Net -0.067 13.454
Foreign Exchange Effects 0.512 -0.447 1.018 0.062 -0.412
Net Change in Cash -20.548 -37.672 -2.296 -189.16 -13.687
Issuance (Retirement) of Debt, Net 0 -69.655 -0.597 -55.813 -0.657
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -16.824 -65.916 -85.058 -71.205 -24.522
Cash From Operating Activities -7.018 -20.924 -29.991 -28.151 -13.637
Cash From Operating Activities 7.913 32.809 24.77 16.976 8.534
Non-Cash Items 1.407 10.485 26.468 25.186 -1.122
Cash Taxes Paid 0.006 0.199 0.133 0.133 0.005
Cash Interest Paid 0 7.157 0.947 0.947 0
Changes in Working Capital 0.486 1.698 3.829 0.892 3.473
Cash From Investing Activities 0 -0.136 -0.259 -0.109 -0.039
Capital Expenditures 0 -0.136 -0.259 -0.109 -0.039
Other Investing Cash Flow Items, Total 0
Cash From Financing Activities 0 0 0 0 0
Financing Cash Flow Items 0 0 0
Issuance (Retirement) of Debt, Net 0 0 0 0 0
Foreign Exchange Effects 0.097 0.512 -0.79 -0.468 -0.092
Net Change in Cash -6.921 -20.548 -31.04 -28.728 -13.768

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Acorda Therapeutics, Inc. Company profile

About Acorda Therapeutics Inc

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. Its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation is used in the development of variety of inhaled medicines. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). It markets Inbrija for intermittent treatment of off episodes, also known as off periods, in people with Parkinson's disease treated with carbidopa/levodopa. Ampyra is a drug to improve walking in adults with multiple sclerosis. Its product pipelines includes ARCUS for acute migraine, Cimaglermin alfa for heart failure and rHIgM22 for multiple sclerosis.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Acorda Therapeutics Inc revenues decreased 16% to $129.1M. Net loss increased 4% to $104M. Revenues reflect License revenue segment decrease from $15M to $0K, Ampyra segment decrease of 14% to $84.6M. Higher net loss reflects Change in fair value of derivative liabi decrease of 97% to $1.2M (income), Changes in fair value of acquired contin increase from $30.9M (income) to $2.9M (expense).

Equity composition

Common Stock $.001 Par, 12/12, 80M auth., 39,804,493 issd. Treasury stock 12,420 shs. at $328K Insiders own 0.24%. IPO: 2/06, 5.5M shs. @ $6.00 by Banc of America Securities LLC,Lazard Capital Markets, Piper Jaffray & SG Cowenn & Co. 6/07, 3.6M Common Stock issd thru privateplacement, by Bank of America & Deuschte Bank & 1.2M shs issd upon conversion.

Industry: Bio Therapeutic Drugs

Two Blue Hill Plaza
PEARL RIVER
NEW YORK 10965
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

BTC/USD

70,297.80 Price
-0.580% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

3,560.04 Price
-0.080% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading